FDA grants accelerated approval to dostarlimab for rectal cancer
The FDA cleared GSK's Jemperli as a stand-alone treatment that may spare some rectal cancer patients surgery.
Objective Facts
The FDA granted accelerated approval on October 19, 2026, to GSK's PD-1 inhibitor dostarlimab (Jemperli) as monotherapy for adults with stage II or III mismatch repair-deficient or microsatellite instability-high locally advanced rectal cancer. Patients receive 500 mg intravenously every three weeks for up to nine cycles, according to The ASCO Post. In the single-arm AZUR-1 trial of 154 patients, the primary endpoint of a sustained clinical complete response at 12 months was met by 47% of patients by independent central review and 68% by investigator review, and GSK said no responders had relapsed after a median follow-up of more than two years. An earlier 50-patient Memorial Sloan Kettering study found a 93% sustained response rate. The FDA said longer follow-up is needed to establish how long responses last, AJMC reported.
Deep Dive
Standard care for locally advanced rectal cancer usually combines chemotherapy, radiation and surgery, which can damage bowel, urinary and sexual function and fertility, Cure Today and AJMC reported. Andrea Cercek of Memorial Sloan Kettering told Fierce Pharma that about 30% of patients under standard care need a permanent colostomy. Her earlier 50-patient study at MSK, in which no patient needed chemoradiation or surgery, led to the larger AZUR-1 trial. An FDA advisory committee voted 8 to 5 in 2023 that single-arm data could support approval in this setting, PharmExec reported. Panelist Jorge Garcia of Case Western Reserve voted no, saying the data were not enough to characterize risks and benefits in a curative setting, according to OncoTherapy Network. The population is small. AJMC cited FDA figures putting dMMR or MSI-H tumors at about 3% of locally advanced rectal cancers, while GSK estimates 5% to 10% of all rectal cancers. The trial has no control arm, and the independent review rate of 47% trails the investigator rate of 68%. GSK says the central figure is still maturing, with 38 more patients holding a complete response but less than 12 months of follow-up. Hesham Abdullah, GSK's global head of oncology R&D, told Fierce Pharma that investigator assessments are probably the most relevant in practice. Serious adverse reactions occurred in 20% of patients and 3% stopped treatment, GSK said. Michael Sapienza, CEO of the Colorectal Cancer Alliance, said biomarker testing at diagnosis will decide who is eligible. Full AZUR-1 interim data are due at the ESMO Congress this month. Continued approval depends on confirmatory evidence, and Fierce Pharma pointed to the phase 3 AZUR-2 trial, expected to read out in 2028. Under Project Orbis, regulators in Canada, Israel, Switzerland and the UK are still reviewing the drug, The ASCO Post reported. Medical Daily noted that cost and insurance coverage remain unclear, and that insurers may require prior authorization and proof of test results.